European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2.
Robert N A KnoblerP ArenbergerA ArunC AssafM BagotG BerlinA BohbotP Calzavara-PintonF ChildA ChoL E FrenchA R GenneryR GniadeckiH P M GollnickE GuenovaP JakschC JantschitschC KlemkeJ LudvigssonE PapadavidJ ScarisbrickT SchwarzR StadlerP WolfJ ZicC ZouboulisA ZuckermannH GreinixPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
These updated 2020 guidelines provide at present the most comprehensive available expert recommendations for the use of extracorporeal photopheresis based on the available published literature and expert consensus opinion. The guidelines were divided into two parts: PART I covers Cutaneous T-cell lymphoma, chronic graft-vs.-host disease and acute graft-vs.-host disease, while PART II will cover scleroderma, solid organ transplantation, Crohn's disease, use of ECP in paediatric patients, atopic dermatitis, type 1 diabetes, pemphigus, epidermolysis bullosa acquisita and erosive oral lichen planus.
Keyphrases
- clinical practice
- type diabetes
- end stage renal disease
- atopic dermatitis
- chronic kidney disease
- ejection fraction
- systematic review
- newly diagnosed
- liver failure
- cardiovascular disease
- systemic sclerosis
- randomized controlled trial
- prognostic factors
- bone marrow
- metabolic syndrome
- drug induced
- patient reported outcomes
- glycemic control
- weight loss
- adipose tissue
- respiratory failure